| Characteristic . | No Fluoroquinolone Prophylaxis (n = 166) . | Fluoroquinolone Prophylaxisb (n = 542) . | Total (N = 708) . | Fisher P Value . |
|---|---|---|---|---|
| Age, y | ||||
| ≤ 29 | 6 (3.6) | 36 (6.6) | 42 (5.9) | .350 |
| 30–49 | 42 (25.3) | 141 (26.0) | 183 (25.8) | |
| ≥ 50 | 118 (71.1) | 365 (67.3) | 483 (68.2) | |
| Sex | ||||
| Female | 65 (39.2) | 207 (38.2) | 272 (38.4) | .855 |
| Male | 101 (60.8) | 335 (61.8) | 436 (61.6) | |
| Race | ||||
| White | 144 (86.7) | 436 (80.4) | 580 (81.9) | .161 |
| Black | 8 (4.8) | 47 (8.7) | 55 (7.8) | |
| Other | 14 (8.4) | 59 (10.9) | 73 (10.3) | |
| Underlying disease | ||||
| Leukemia | 87 (52.4) | 273 (50.4) | 360 (50.8) | .752 |
| Lymphoma | 29 (17.5) | 84 (15.5) | 113 (16.0) | |
| Myeloproliferative disorder | 6 (3.6) | 28 (5.2) | 34 (4.8) | |
| Other | 44 (26.5) | 157 (29.0) | 201 (28.4) | |
| Risk | ||||
| High | 52 (31.3) | 146 (26.9) | 198 (28.0) | .502 |
| Intermediate | 33 (19.9) | 123 (22.7) | 156 (22.0) | |
| Low/not applicable | 81 (48.8) | 273 (50.4) | 354 (50.0) | |
| HCT source | ||||
| Related identical | 48 (28.9) | 128 (23.6) | 176 (24.9) | .269 |
| Unrelated identical | 71 (42.8) | 225 (41.5) | 296 (41.8) | |
| Cord blood | 22 (13.3) | 103 (19.0) | 125 (17.7) | |
| Other | 25 (15.1) | 86 (15.9) | 111 (15.7) | |
| Conditioning intensity | ||||
| Myeloablative | 88 (53.0) | 284 (52.4) | 372 (52.5) | .004 |
| Reduced intensity | 51 (30.7) | 215 (39.7) | 266 (37.6) | |
| Nonmyeloablative | 27 (16.3) | 43 (7.9) | 70 (9.9) | |
| Graft manipulation: ex vivo T-cell depleted graft | 85 (51.2) | 220 (40.6) | 305 (43.1) | .020 |
| Time to engraftment ≥ 14 d | 38 (22.9) | 203 (37.5) | 241 (34.0) | .001 |
| Pre-HCT history of prior gram-negative BSI (60 d) | 3 (1.8) | 15 (3) | 18 (2.5) | .778 |
| Other prophylactic antibiotic administrationb | ||||
| TMP-SMX | 43 (25.9) | 182 (34) | 225 (31.8) | .070 |
| Vancomycin (IV) | 138 (83.1) | 518 (95.6) | 656 (92.7) | .000 |
| Gram-negative bloodstream infection detected | 19 (11.4) | 34 (6.3) | 53 (7.5) | .041 |
| Characteristic . | No Fluoroquinolone Prophylaxis (n = 166) . | Fluoroquinolone Prophylaxisb (n = 542) . | Total (N = 708) . | Fisher P Value . |
|---|---|---|---|---|
| Age, y | ||||
| ≤ 29 | 6 (3.6) | 36 (6.6) | 42 (5.9) | .350 |
| 30–49 | 42 (25.3) | 141 (26.0) | 183 (25.8) | |
| ≥ 50 | 118 (71.1) | 365 (67.3) | 483 (68.2) | |
| Sex | ||||
| Female | 65 (39.2) | 207 (38.2) | 272 (38.4) | .855 |
| Male | 101 (60.8) | 335 (61.8) | 436 (61.6) | |
| Race | ||||
| White | 144 (86.7) | 436 (80.4) | 580 (81.9) | .161 |
| Black | 8 (4.8) | 47 (8.7) | 55 (7.8) | |
| Other | 14 (8.4) | 59 (10.9) | 73 (10.3) | |
| Underlying disease | ||||
| Leukemia | 87 (52.4) | 273 (50.4) | 360 (50.8) | .752 |
| Lymphoma | 29 (17.5) | 84 (15.5) | 113 (16.0) | |
| Myeloproliferative disorder | 6 (3.6) | 28 (5.2) | 34 (4.8) | |
| Other | 44 (26.5) | 157 (29.0) | 201 (28.4) | |
| Risk | ||||
| High | 52 (31.3) | 146 (26.9) | 198 (28.0) | .502 |
| Intermediate | 33 (19.9) | 123 (22.7) | 156 (22.0) | |
| Low/not applicable | 81 (48.8) | 273 (50.4) | 354 (50.0) | |
| HCT source | ||||
| Related identical | 48 (28.9) | 128 (23.6) | 176 (24.9) | .269 |
| Unrelated identical | 71 (42.8) | 225 (41.5) | 296 (41.8) | |
| Cord blood | 22 (13.3) | 103 (19.0) | 125 (17.7) | |
| Other | 25 (15.1) | 86 (15.9) | 111 (15.7) | |
| Conditioning intensity | ||||
| Myeloablative | 88 (53.0) | 284 (52.4) | 372 (52.5) | .004 |
| Reduced intensity | 51 (30.7) | 215 (39.7) | 266 (37.6) | |
| Nonmyeloablative | 27 (16.3) | 43 (7.9) | 70 (9.9) | |
| Graft manipulation: ex vivo T-cell depleted graft | 85 (51.2) | 220 (40.6) | 305 (43.1) | .020 |
| Time to engraftment ≥ 14 d | 38 (22.9) | 203 (37.5) | 241 (34.0) | .001 |
| Pre-HCT history of prior gram-negative BSI (60 d) | 3 (1.8) | 15 (3) | 18 (2.5) | .778 |
| Other prophylactic antibiotic administrationb | ||||
| TMP-SMX | 43 (25.9) | 182 (34) | 225 (31.8) | .070 |
| Vancomycin (IV) | 138 (83.1) | 518 (95.6) | 656 (92.7) | .000 |
| Gram-negative bloodstream infection detected | 19 (11.4) | 34 (6.3) | 53 (7.5) | .041 |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; HCT, hematopoietic cell transplantation; IV, intravenous; TMP-SMX, trimethoprim-sulfamethoxazole.
aSix hundred ninety-six individual patients; 12 patients underwent allogeneic HCT on 2 separate occasions.
bAll prophylaxis agents (fluoroquinolones, TMP-SMX, and vancomycin IV) were given starting HCT day −2 or earlier.
| Characteristic . | No Fluoroquinolone Prophylaxis (n = 166) . | Fluoroquinolone Prophylaxisb (n = 542) . | Total (N = 708) . | Fisher P Value . |
|---|---|---|---|---|
| Age, y | ||||
| ≤ 29 | 6 (3.6) | 36 (6.6) | 42 (5.9) | .350 |
| 30–49 | 42 (25.3) | 141 (26.0) | 183 (25.8) | |
| ≥ 50 | 118 (71.1) | 365 (67.3) | 483 (68.2) | |
| Sex | ||||
| Female | 65 (39.2) | 207 (38.2) | 272 (38.4) | .855 |
| Male | 101 (60.8) | 335 (61.8) | 436 (61.6) | |
| Race | ||||
| White | 144 (86.7) | 436 (80.4) | 580 (81.9) | .161 |
| Black | 8 (4.8) | 47 (8.7) | 55 (7.8) | |
| Other | 14 (8.4) | 59 (10.9) | 73 (10.3) | |
| Underlying disease | ||||
| Leukemia | 87 (52.4) | 273 (50.4) | 360 (50.8) | .752 |
| Lymphoma | 29 (17.5) | 84 (15.5) | 113 (16.0) | |
| Myeloproliferative disorder | 6 (3.6) | 28 (5.2) | 34 (4.8) | |
| Other | 44 (26.5) | 157 (29.0) | 201 (28.4) | |
| Risk | ||||
| High | 52 (31.3) | 146 (26.9) | 198 (28.0) | .502 |
| Intermediate | 33 (19.9) | 123 (22.7) | 156 (22.0) | |
| Low/not applicable | 81 (48.8) | 273 (50.4) | 354 (50.0) | |
| HCT source | ||||
| Related identical | 48 (28.9) | 128 (23.6) | 176 (24.9) | .269 |
| Unrelated identical | 71 (42.8) | 225 (41.5) | 296 (41.8) | |
| Cord blood | 22 (13.3) | 103 (19.0) | 125 (17.7) | |
| Other | 25 (15.1) | 86 (15.9) | 111 (15.7) | |
| Conditioning intensity | ||||
| Myeloablative | 88 (53.0) | 284 (52.4) | 372 (52.5) | .004 |
| Reduced intensity | 51 (30.7) | 215 (39.7) | 266 (37.6) | |
| Nonmyeloablative | 27 (16.3) | 43 (7.9) | 70 (9.9) | |
| Graft manipulation: ex vivo T-cell depleted graft | 85 (51.2) | 220 (40.6) | 305 (43.1) | .020 |
| Time to engraftment ≥ 14 d | 38 (22.9) | 203 (37.5) | 241 (34.0) | .001 |
| Pre-HCT history of prior gram-negative BSI (60 d) | 3 (1.8) | 15 (3) | 18 (2.5) | .778 |
| Other prophylactic antibiotic administrationb | ||||
| TMP-SMX | 43 (25.9) | 182 (34) | 225 (31.8) | .070 |
| Vancomycin (IV) | 138 (83.1) | 518 (95.6) | 656 (92.7) | .000 |
| Gram-negative bloodstream infection detected | 19 (11.4) | 34 (6.3) | 53 (7.5) | .041 |
| Characteristic . | No Fluoroquinolone Prophylaxis (n = 166) . | Fluoroquinolone Prophylaxisb (n = 542) . | Total (N = 708) . | Fisher P Value . |
|---|---|---|---|---|
| Age, y | ||||
| ≤ 29 | 6 (3.6) | 36 (6.6) | 42 (5.9) | .350 |
| 30–49 | 42 (25.3) | 141 (26.0) | 183 (25.8) | |
| ≥ 50 | 118 (71.1) | 365 (67.3) | 483 (68.2) | |
| Sex | ||||
| Female | 65 (39.2) | 207 (38.2) | 272 (38.4) | .855 |
| Male | 101 (60.8) | 335 (61.8) | 436 (61.6) | |
| Race | ||||
| White | 144 (86.7) | 436 (80.4) | 580 (81.9) | .161 |
| Black | 8 (4.8) | 47 (8.7) | 55 (7.8) | |
| Other | 14 (8.4) | 59 (10.9) | 73 (10.3) | |
| Underlying disease | ||||
| Leukemia | 87 (52.4) | 273 (50.4) | 360 (50.8) | .752 |
| Lymphoma | 29 (17.5) | 84 (15.5) | 113 (16.0) | |
| Myeloproliferative disorder | 6 (3.6) | 28 (5.2) | 34 (4.8) | |
| Other | 44 (26.5) | 157 (29.0) | 201 (28.4) | |
| Risk | ||||
| High | 52 (31.3) | 146 (26.9) | 198 (28.0) | .502 |
| Intermediate | 33 (19.9) | 123 (22.7) | 156 (22.0) | |
| Low/not applicable | 81 (48.8) | 273 (50.4) | 354 (50.0) | |
| HCT source | ||||
| Related identical | 48 (28.9) | 128 (23.6) | 176 (24.9) | .269 |
| Unrelated identical | 71 (42.8) | 225 (41.5) | 296 (41.8) | |
| Cord blood | 22 (13.3) | 103 (19.0) | 125 (17.7) | |
| Other | 25 (15.1) | 86 (15.9) | 111 (15.7) | |
| Conditioning intensity | ||||
| Myeloablative | 88 (53.0) | 284 (52.4) | 372 (52.5) | .004 |
| Reduced intensity | 51 (30.7) | 215 (39.7) | 266 (37.6) | |
| Nonmyeloablative | 27 (16.3) | 43 (7.9) | 70 (9.9) | |
| Graft manipulation: ex vivo T-cell depleted graft | 85 (51.2) | 220 (40.6) | 305 (43.1) | .020 |
| Time to engraftment ≥ 14 d | 38 (22.9) | 203 (37.5) | 241 (34.0) | .001 |
| Pre-HCT history of prior gram-negative BSI (60 d) | 3 (1.8) | 15 (3) | 18 (2.5) | .778 |
| Other prophylactic antibiotic administrationb | ||||
| TMP-SMX | 43 (25.9) | 182 (34) | 225 (31.8) | .070 |
| Vancomycin (IV) | 138 (83.1) | 518 (95.6) | 656 (92.7) | .000 |
| Gram-negative bloodstream infection detected | 19 (11.4) | 34 (6.3) | 53 (7.5) | .041 |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; HCT, hematopoietic cell transplantation; IV, intravenous; TMP-SMX, trimethoprim-sulfamethoxazole.
aSix hundred ninety-six individual patients; 12 patients underwent allogeneic HCT on 2 separate occasions.
bAll prophylaxis agents (fluoroquinolones, TMP-SMX, and vancomycin IV) were given starting HCT day −2 or earlier.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
